Does TOFACITINIB Cause Interstitial lung disease? 645 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 645 reports of Interstitial lung disease have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.4% of all adverse event reports for TOFACITINIB.
645
Reports of Interstitial lung disease with TOFACITINIB
0.4%
of all TOFACITINIB reports
132
Deaths
247
Hospitalizations
How Dangerous Is Interstitial lung disease From TOFACITINIB?
Of the 645 reports, 132 (20.5%) resulted in death, 247 (38.3%) required hospitalization, and 121 (18.8%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for TOFACITINIB.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which TOFACITINIB Alternatives Have Lower Interstitial lung disease Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN